玻璃体内注射齐夫-阿柏西普治疗渗出性年龄相关性黄斑变性后的临床与电生理评估
该研究纳入15例单侧渗出性年龄相关性黄斑变性患者,评估玻璃体内注射齐夫-阿柏西普(1.25 mg)治疗6个月的安全性和有效性。所有患者接受每月三次注射后按需治疗。结果显示最佳矫正视力、黄斑中心凹厚度、黄斑总体积及多焦视网膜电图振幅均显著改善,全视野视网膜电图未显示视网膜毒性,无全身或眼部并发症。
要点
- 玻璃体内注射齐夫-阿柏西普1.25 mg每月三次后按需治疗,26周时最佳矫正视力logMAR从0.93±0.4改善至0.82±0.5(P=0.00408)。
- 黄斑中心凹厚度从490.3±155.1微米显著降至327.9±101.5微米(P=0.0007),黄斑总体积从9.51±1.36 mm降至8.08±1.34 mm(P<0.0001)。
- 多焦视网膜电图中央15°内P1振幅在26周时显著增加(P<0.05),全视野视网膜电图除a波隐含时间增加外其他参数无差异,无视网膜毒性。
核心结论
- 玻璃体内注射齐夫-阿柏西普从基线至26周显著改善最佳矫正视力、多焦视网膜电图振幅、黄斑中心凹厚度和黄斑总体积。
- 随访期间全视野视网膜电图未显示视网膜毒性,无不良事件发生。
研究设计与样本
- 研究纳入15例单侧渗出性年龄相关性黄斑变性患者,评估玻璃体内注射齐夫-阿柏西普(1.25 mg)治疗6个月的安全性和有效性。
- 所有患者接受每月三次玻璃体内注射齐夫-阿柏西普(1.25 mg),随后按需治疗。
- 在基线及每月测量最佳矫正视力并进行谱域光学相干断层扫描;在基线及首次注射后4、13、26周进行全视野视网膜电图和多焦视网膜电图检查。
主要发现
- 基线至26周,平均logMAR最佳矫正视力从0.93±0.4(20/200)改善至0.82±0.5(20/160)(P=0.00408)。
- 黄斑中心凹厚度从490.3±155.1微米显著降至327.9±101.5微米(P=0.0007)。
- 平均黄斑总体积从9.51±1.36 mm显著降至8.08±1.34 mm(P<0.0001)。
- 全视野视网膜电图a波隐含时间增加,其他全视野视网膜电图参数无差异。
- 多焦视网膜电图中央15°内平均黄斑反应在26周时P1振幅显著增加(P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal injections for treating exudative age-related macular degeneration. METHODS: Fifteen patients with unilateral exudative age-related macular degeneration were enrolled. The best-corrected visual acuity was measured and spectral domain optical coherence tomography was performed at baseline and monthly. Full-field electroretinography and multifocal electroretinography were obtained at baseline and 4, 13, and 26 weeks after the first injection. All patients received three monthly intravitreal injections of ziv-aflibercept (1.25 mg) followed by as-needed treatment. RESULTS: Between baseline and 26 weeks, the mean logMAR best-corrected visual acuity improved (P = 0.00408) from 0.93 ± 0.4 (20/200) to 0.82 ± 0.5 (20/160) logarithm of the minimum angle of resolution, respectively; the central retinal thickness decreased significantly (P = 0.0007) from 490.3 ± 155.1 microns to 327.9 ± 101.5 microns; the mean total macular volume decreased significantly (P < 0.0001) from 9.51 ± 1.36 mm to 8.08 ± 1.34 mm, and the a-wave implicit time increased, with no differences in the other full-field electroretinography parameters. The average multifocal electroretinography macular responses within the first central 15° showed significantly (P < 0.05) increased P1 amplitudes at 26 weeks. No systemic or ocular complications developed. CONCLUSION: Intravitreal ziv-aflibercept significantly improved the best-corrected visual acuity, multifocal electroretinography amplitudes, central retinal thickness, and total macular volume from baseline to 26 weeks. No retinal toxicity on full-field electroretinography or adverse events occurred during the follow-up period.
引用
- de Oliveira Dias JR, de Andrade GC, Kniggendorf VF, et al. CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina. 2017. PMID: 27798520. doi:10.1097/IAE.0000000000001385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。